<DOC>
	<DOC>NCT02805504</DOC>
	<brief_summary>A prospective, randomized controlled study to determine the efficacy of liposomal bupivacaine given by local injection at all the wound sites in patients undergoing urologic surgeries.</brief_summary>
	<brief_title>Liposomal Bupivacaine for Postoperative Pain Control in Urologic Procedures</brief_title>
	<detailed_description>A prospective, randomized controlled study to determine the efficacy of liposomal bupivacaine given by local injection at all the wound sites in patients undergoing urologic surgeries. Subjects of prospective study will be randomly divided using electronic program into two groups: The first group will receive intraoperative local Liposomal Bupivacaine injection at the port placement site. The control group will receive will local Marcaine (bupivacaine HCl) injection Primary Outcome Measures: - Total opioid consumption measured in intravenous morphine equivalents dose during the postoperative hospital Stay - Postoperative pain assessment using visual Analog Pain Scores &amp; Brief Pain Inventory form. - Length of Hospital Stay - Time to First Opioid Use. - Postoperative Constipation , paralytic ileus</detailed_description>
	<mesh_term>Pain, Postoperative</mesh_term>
	<mesh_term>Urologic Diseases</mesh_term>
	<mesh_term>Bupivacaine</mesh_term>
	<criteria>Patients undergoing urologic surgery. Pregnant and/or nursing mothers. Allergy to bupivacaine. History of drug/alcohol abuse. Severe cardiovascular, hepatic, renal disease or neurological impairment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Bupivacaine</keyword>
	<keyword>Minimally Invasive Surgical Procedures</keyword>
</DOC>